<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105607</url>
  </required_header>
  <id_info>
    <org_study_id>D-4517-001</org_study_id>
    <nct_id>NCT05105607</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants</brief_title>
  <official_title>A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 (Hydroxyl Dendrimer VEGFR Tyrosine Kinase Inhibitor) After Subcutaneous Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ashvattha Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ashvattha Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of D-4517.2&#xD;
      after single subcutaneous (SC) doses in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Day 1 up to Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of D-4517.2</measure>
    <time_frame>Day 1 up to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (tmax) of D-4517.2</measure>
    <time_frame>Day 1 up to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant (kel) of D-4517.2</measure>
    <time_frame>Day 1 up to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Half-life (t1/2) of D-4517.2</measure>
    <time_frame>Day 1 up to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve Based On the Last Measurable Concentration (AUC0-t)</measure>
    <time_frame>Day 1 up to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve from Time Zero to Infinity (AUC0-inf)</measure>
    <time_frame>Day 1 up to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of D-4517.2</measure>
    <time_frame>Day 1 up to Day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 0.5 mg/kg D-4517.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered a single dose of 0.5 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the safety review committee (SRC) will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 1.0 mg/kg D-4517.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered a single dose of 1.0 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: 2.0 mg/kg D-4517.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered a single dose of 2.0 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: 4.0 mg/kg D-4517.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered 4.0 mg/kg D-4517.2 as two subcutaneous (SC) injections. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-4517.2</intervention_name>
    <description>Subcutaneous (SC) injection</description>
    <arm_group_label>Cohort 1: 0.5 mg/kg D-4517.2</arm_group_label>
    <arm_group_label>Cohort 2: 1.0 mg/kg D-4517.2</arm_group_label>
    <arm_group_label>Cohort 3: 2.0 mg/kg D-4517.2</arm_group_label>
    <arm_group_label>Cohort 4: 4.0 mg/kg D-4517.2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is a healthy man or woman age 18 to 65 years, inclusive, at the Screening Visit;&#xD;
&#xD;
          2. Has the ability to understand and sign the written informed consent form (ICF) and&#xD;
             local medical privacy authorization forms, which must be obtained prior to any study&#xD;
             related procedures being completed;&#xD;
&#xD;
          3. Body mass index (BMI) between 18 and 32 kg/m^2, inclusive, with body weight ≤ 100 kg;&#xD;
&#xD;
          4. Is in general good health, based upon the results of a medical history assessment,&#xD;
             physical examination, vital signs, and laboratory profile, as judged by the&#xD;
             Investigator;&#xD;
&#xD;
          5. Female participants of non-childbearing potential must be either surgically sterile&#xD;
             (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy&#xD;
             at least 26 weeks before the Screening Visit) or postmenopausal, defined as&#xD;
             spontaneous amenorrhea for at least 1 years, with follicle-stimulating hormone (FSH)&#xD;
             in the postmenopausal range at screening, based on the central laboratory's ranges;&#xD;
&#xD;
          6. Female participants of childbearing potential (i.e., ovulating, premenopausal, and not&#xD;
             surgically sterile) and all male participants must use a medically accepted&#xD;
             contraceptive regimen (including hormonal contraceptives) during their participation&#xD;
             in the study and for 30 days after the last administration of study drug. Medically&#xD;
             accepted contraceptive methods are defined as those with 90% or greater efficacy;&#xD;
&#xD;
          7. Acceptable methods of contraception for male participants enrolled in the study&#xD;
             include the following:&#xD;
&#xD;
             • Condoms or surgical sterilization of participant at least 26 weeks before the&#xD;
             Screening Visit (vasectomy);&#xD;
&#xD;
             Acceptable methods of contraception for female participants enrolled in the study&#xD;
             include the following:&#xD;
&#xD;
               -  Surgical sterilization of participant at least 26 weeks before the Screening&#xD;
                  Visit (includes hysterectomy or bilateral tubal ligation, oophorectomy, or&#xD;
                  salpingectomy);&#xD;
&#xD;
               -  Intrauterine device for at least 4 weeks before the Screening Visit; or&#xD;
&#xD;
               -  Hormonal contraception (oral, implant, injection, ring, or patch) for at least 4&#xD;
                  weeks before the Screening Visit;&#xD;
&#xD;
          8. If male, participants must agree to abstain from sperm donation through 90 days after&#xD;
             administration of the last dose of study drug;&#xD;
&#xD;
          9. Female participants may not be pregnant, lactating, or breastfeeding;&#xD;
&#xD;
         10. Female participants of childbearing potential must have negative result for pregnancy&#xD;
             test at screening and Check-in;&#xD;
&#xD;
         11. Participants must have a negative test result for hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis C virus antibody (HCVab), and human immunodeficiency virus (HIV) antibody at&#xD;
             screening;&#xD;
&#xD;
         12. Participants must have an estimated glomerular filtration rate (eGFR) of ≥45&#xD;
             mL/min/1.73m^2 at screening;&#xD;
&#xD;
         13. Participants must have a negative urine test for drugs of abuse (see Appendix B),&#xD;
             cotinine, and breath alcohol test at screening and Check-in; and&#xD;
&#xD;
         14. Participants must be willing and able to abide by all study requirements and&#xD;
             restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of clinically significant hematologic, renal, endocrine, pulmonary, cardiac,&#xD;
             gastrointestinal (GI), hepatic, psychiatric, neurologic, immunologic, allergic disease&#xD;
             (including multiple or clinically significant drug allergies), or any other condition&#xD;
             that, in the opinion of the Investigator, might significantly interfere with the&#xD;
             absorption, distribution, metabolism, or excretion of study drug, or place the&#xD;
             participant at an unacceptable risk as a participant in this study;&#xD;
&#xD;
          2. Evidence of systemic inflammation as measured by C-reactive protein above the upper&#xD;
             limit of normal as measured by local lab;&#xD;
&#xD;
          3. History of malignancy (other than successfully treated basal cell or squamous cell&#xD;
             skin cancer);&#xD;
&#xD;
          4. History or presence of an abnormal ECG that, in the opinion of the Investigator, is&#xD;
             clinically significant;&#xD;
&#xD;
          5. Laboratory results (serum chemistry, hematology, coagulation, and urinalysis) outside&#xD;
             the normal range at screening and Check-in and considered clinically significant in&#xD;
             the opinion of the Investigator. Any elevation of aspartate transaminase (AST) and&#xD;
             alanine transaminase (ALT) above the upper limit of normal at screening and/or&#xD;
             Check-in is exclusionary. One retest of an exclusionary laboratory result is allowed&#xD;
             at the discretion of the Investigator;&#xD;
&#xD;
          6. Has had an acute illness considered clinically significant by the Investigator within&#xD;
             30 days prior to screening;&#xD;
&#xD;
          7. History of alcoholism or drug abuse within 2 years prior to screening;&#xD;
&#xD;
          8. Has used any product containing nicotine within 90 days prior to screening or intends&#xD;
             to use any product containing nicotine during the course of the study;&#xD;
&#xD;
          9. Has had any immunizations (live vaccines) in the 4 weeks prior to screening; COVID-19&#xD;
             vaccination within 7 days of Day 1;&#xD;
&#xD;
         10. Has used medications that affect GI motility or gastric emptying; such as&#xD;
             metoclopramide, proton pump inhibitors, and H2 blockers; within 30 days prior to Day&#xD;
             1;&#xD;
&#xD;
         11. Has used any prescription or over-the-counter medication (with exception of&#xD;
             acetaminophen), vitamins/herbal supplements (with the exception of hormonal&#xD;
             contraceptives) within 14 days prior to Day 1;&#xD;
&#xD;
         12. Has used any other study drug within 30 days or 5 half-lives of the drug (whichever is&#xD;
             longer) prior to Day 1;&#xD;
&#xD;
         13. Has lost or donated &gt;450 mL of whole blood or blood products within 30 days prior to&#xD;
             screening;&#xD;
&#xD;
         14. Investigator has reason to believe that the participant may be unable to fulfill the&#xD;
             protocol visit schedule or requirements;&#xD;
&#xD;
         15. Has any finding that, in the view of the Investigator or Medical Monitor, would&#xD;
             compromise the participant's safety requirements; or&#xD;
&#xD;
         16. Is employed by the Sponsor, the Contract Research Organization (CRO), or the study&#xD;
             site (permanent, temporary contract worker, or designee responsible for the conduct of&#xD;
             the study), or is a family member (spouse, parent, sibling, or child) of the Sponsor,&#xD;
             CRO, or study site employee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>D-4517.2</keyword>
  <keyword>Neovascular Age-related Macular Degeneration</keyword>
  <keyword>Diabetic Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

